Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): Head-to-Head Efficacy

Mechanism of Action: Same Class, Different Molecules

Both tadalafil and vardenafil belong to the phosphodiesterase type 5 (PDE5) inhibitor class. They block PDE5 enzyme degradation of cyclic guanosine monophosphate (cGMP) in penile smooth muscle, allowing nitric oxide-mediated vasodilation during sexual stimulation.

The molecular differences matter clinically. Tadalafil has a methylenedioxyphenyl group that gives it a plasma half-life of 17.5 hours, roughly 4x longer than vardenafil's 4-5 hour half-life 1. This extended duration underpins tadalafil's unique daily-dosing approval. Vardenafil's piperazine ring structure provides higher PDE5 selectivity (IC50 of 0.7 nM vs tadalafil's 5 nM), though this laboratory-level potency difference has not translated into clinically superior erection outcomes in comparative trials 2.

Tadalafil also inhibits PDE11, found in skeletal muscle and testes, which may explain the mild myalgia some patients report. Vardenafil has minimal PDE11 activity but moderate PDE6 cross-reactivity, producing occasional visual disturbances similar to sildenafil.

Efficacy in Clinical Trials: What the Data Shows

No single large randomized controlled trial directly compares tadalafil to vardenafil head-to-head. The available evidence comes from cross-trial synthesis of similarly designed placebo-controlled studies.

In the key tadalafil registration trial by Brock et al. (2002, N=1,112), tadalafil 20 mg improved the IIEF-EF domain score by a mean of 7.9 points from baseline versus 1.2 points for placebo. Successful intercourse attempts (SEP3) reached 73% at 20 mg compared with 32% for placebo 1. The study also demonstrated that efficacy persisted at 24 and 36 hours post-dose, a finding unique among PDE5 inhibitors at that time.

For vardenafil, the Porst et al. (2003) trial enrolled 580 men with ED (including a diabetic subpopulation) and found that vardenafil 20 mg improved IIEF-EF scores by 8.8 points versus 2.6 points for placebo. SEP3 rates reached 75% at 20 mg 2. These results held even in the diabetes subgroup, where vardenafil 20 mg produced a 72% SEP3 rate.

A 2006 meta-analysis published in European Urology pooled 82 RCTs covering all three major PDE5 inhibitors and found no statistically significant difference in overall efficacy between tadalafil 20 mg and vardenafil 20 mg (OR for IIEF improvement: 3.8 vs 4.1, overlapping confidence intervals) 3.

Onset and Duration: The Key Clinical Differentiator

The pharmacokinetic profiles of these two drugs create distinct use-case scenarios that matter to patients daily.

Vardenafil reaches Tmax (peak plasma concentration) in 0.7-0.9 hours, making it one of the fastest-acting PDE5 inhibitors. The orally disintegrating tablet formulation (Staxyn) achieves Tmax even faster at approximately 45 minutes and can be taken without water 4. Clinical data suggest that 25% of men on vardenafil achieve erections sufficient for penetration within 15-20 minutes of dosing.

Tadalafil reaches Tmax at approximately 2 hours, but its 36-hour window of efficacy means that timing intercourse around a single dose is unnecessary. The Endocrine Society's 2018 clinical practice guideline notes that this extended duration may reduce performance anxiety associated with timed dosing 5.

For men who have sex two or more times per week, tadalafil 5 mg daily produces steady-state plasma levels that eliminate the need for pre-planned dosing entirely. A 2007 study by Porst et al. found daily tadalafil 5 mg produced IIEF-EF improvements of 6.4 points, comparable to on-demand 20 mg dosing (7.0 points), with the added benefit of continuous readiness 6.

Efficacy in Special Populations

Diabetes-Associated ED

Both drugs have strong efficacy in men with diabetes, a population where ED severity tends to be greater. Porst et al. (2003) specifically demonstrated vardenafil's efficacy in diabetic men, with SEP3 rates of 72% at 20 mg 2. A separate 12-week RCT of tadalafil in 216 diabetic men showed 64% SEP3 at 20 mg versus 25% for placebo 7.

Vardenafil may have a slight numerical advantage in this subgroup, though no direct comparison trial exists. The AUA Guidelines (2018) state: "All PDE5 inhibitors are effective in diabetic ED; choice should be guided by patient preference regarding onset and duration" 8.

BPH/LUTS

Tadalafil 5 mg daily holds an FDA-approved indication for benign prostatic hyperplasia with lower urinary tract symptoms (BPH/LUTS), based on multiple RCTs showing 2.0-2.8 point improvements in IPSS scores 9. Vardenafil has no such indication. For men with concurrent ED and BPH, tadalafil daily addresses both conditions with a single tablet. The 2023 EAU Guidelines recommend daily tadalafil as first-line for men with moderate LUTS and concurrent ED 10.

Post-Prostatectomy

Penile rehabilitation after radical prostatectomy typically employs nightly or daily PDE5 inhibitor dosing to preserve cavernosal smooth muscle oxygenation. Tadalafil's long half-life makes it the preferred agent in this context. Montorsi et al. (2008) showed that daily tadalafil 5 mg post-prostatectomy produced recovery of spontaneous erections in 25.2% of patients versus 14.2% for placebo at 9 months 11.

Side Effect Profiles Compared

PDE5 inhibitors share a common side-effect spectrum (headache, flushing, nasal congestion, dyspepsia), but each molecule has distinct patterns.

Tadalafil's most characteristic adverse effects are back pain and myalgia, reported in 5-7% of patients on 20 mg. These effects are attributed to PDE11 inhibition in skeletal muscle. Because tadalafil's long half-life means sustained drug exposure, these effects can persist for 12-24 hours 1.

Vardenafil produces headache (15%) and flushing (11%) at rates slightly higher than tadalafil (headache 14%, flushing 4%). Vardenafil also carries a mild QTc prolongation warning: a mean increase of 8 ms at 40 mg dose. The FDA label contraindicates vardenafil use with Class IA or Class III antiarrhythmics 12. Tadalafil carries no equivalent cardiac conduction warning.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has noted: "The safety profiles of PDE5 inhibitors are reassuringly similar across the class, but clinicians should match the specific side-effect pattern to the individual patient's comorbidities and preferences."

Cost and Access: Generic Market Reality

Since tadalafil lost patent exclusivity in 2018, generic pricing has dropped substantially. Current cash-pay prices for generic tadalafil range from $0.50-3.00 per tablet (5-20 mg) at major US pharmacies. Vardenafil generics became available in 2018 as well, but pricing remains higher at $2-8 per tablet due to lower prescribing volume and less competitive manufacturing.

Daily tadalafil 5 mg at $1 per tablet costs approximately $30/month. On-demand vardenafil 20 mg at $4 per tablet costs $16-32/month assuming 4-8 uses. For men with high-frequency sexual activity, daily tadalafil may be more cost-effective than on-demand vardenafil once use exceeds 7-8 times monthly 13.

Insurance coverage varies. Many commercial plans cover 6-8 tablets per month of either drug with prior authorization confirming an ED diagnosis. The Staxyn orally disintegrating formulation of vardenafil typically has higher copays than film-coated vardenafil generics.

Patient Selection: Matching Drug to Lifestyle

The American Urological Association's 2018 Erectile Dysfunction Guideline does not recommend one PDE5 inhibitor over another as universally superior 8. Selection depends on patient-specific factors.

Choose tadalafil when:

• Sexual frequency is 2+ times per week (daily dosing eliminates planning)
• Patient has concurrent BPH/LUTS
• Patient reports performance anxiety related to timing
• Patient eats high-fat meals close to sexual activity (no food interaction)
• Post-prostatectomy penile rehabilitation is indicated

Choose vardenafil when:

• Patient wants the fastest possible onset (particularly Staxyn ODT)
• Sexual activity is infrequent (1-2 times per month) and on-demand dosing is preferred
• Patient experienced back pain or myalgia on tadalafil
• Patient prefers a shorter drug-exposure window

The European Association of Urology 2023 Male Sexual Dysfunction Guidelines state: "PDE5 inhibitor selection should be individualized. Patients who fail one agent should trial at least two others before being classified as PDE5 inhibitor non-responders" 10.

Switching Between Agents

Cross-titration between tadalafil and vardenafil requires no washout period. The drugs do not interact, and switching can occur immediately between on-demand agents. When transitioning from daily tadalafil 5 mg to on-demand vardenafil, waiting 3-4 days (approximately 5 half-lives of tadalafil) before taking vardenafil eliminates any theoretical overlap, though concurrent PDE5 inhibitor use at standard doses has not demonstrated additive hypotension risk in healthy men 14.

A crossover preference study by Eardley et al. (2005, N=291) found that when men tried both tadalafil and a short-acting PDE5 inhibitor (sildenafil) for 12 weeks each, 73% preferred tadalafil, primarily citing "lack of time pressure" and "naturalness" of the longer-acting option. While this specific study did not include vardenafil, the pharmacokinetic principle applies identically given vardenafil's similarly short 4-5 hour window 15.

Drug Interactions and Contraindications

Both drugs are contraindicated with nitrates (absolute), alpha-blockers require dose adjustment, and strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase exposure of both.

Vardenafil carries the additional QTc contraindication. Men taking sotalol, amiodarone, procainamide, or quinidine should not use vardenafil 12. Tadalafil does not prolong QTc at therapeutic doses and has no antiarrhythmic contraindication.

For men on tamsulosin for BPH, both drugs can be coadministered safely, though orthostatic caution applies. Tadalafil 5 mg daily with tamsulosin 0.4 mg is the most studied combination, with no clinically meaningful blood pressure interaction in the MUSTT extension data.

The Bottom Line for Clinicians

The clinical efficacy of tadalafil 20 mg and vardenafil 20 mg for erectile dysfunction is equivalent based on available trial data. SEP3 rates cluster at 65-75% for both drugs in broad ED populations. The choice between them should be driven by duration preference, dosing frequency, comorbid BPH, cardiac conduction history, and cost sensitivity. Men who do not respond adequately to one PDE5 inhibitor at maximal dose should trial the other before concluding PDE5 inhibitor failure. For daily therapy candidates, tadalafil 5 mg remains the only FDA-approved option in this two-drug comparison.